Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 3/20 | 0.50 |
| ▸ | TACR2 | P21452 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nolpitantium SCHEMBL7561842 | 0.91 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29405138 | 0.91 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29721569 | 0.91 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL1650319 | 0.91 | TACR2 (0.61) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29388081 | 0.90 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL2142512 | 0.90 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL6350205 | 0.90 | TACR2 (0.62) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL157084 | 0.85 | TACR2 (0.56) | TACR2TACR1CCR5 | |
| Nolpitantium SCHEMBL29457709 | 0.85 | TACR2 (0.56) | TACR2TACR1CCR5 | |
| SCHEMBL8969597 | 0.78 | TACR2 (0.53) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | TACR1 12/4885TACR2 44/4885CCR5 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.